Retina specialists share their perspectives on evolving anti-VEGF therapy, pipeline treatments, and strategies to enhance patient outcomes.
David Almeida, MD, MBA, PhD
Advertisement
Articles by David Almeida, MD, MBA, PhD
Dr David Almeida shares two cases of neovascular AMD from his practice, one treatment-naïve and one previously treated, and presents his findings after switching them to faricimab.
David Almeida, MD, MBA, PhD, reviews the objectives and design of the TRUCKEE study, and discusses the visual and anatomic outcomes after one and three injections of faricimab in neovascular AMD.
Advertisement
Latest Updated Articles
Two Faricimab Patient Cases from the Real-world in Neovascular AMDPublished: April 18th 2023 | Updated:
Evolving strategies in retinal care: Navigating today’s treatment landscapePublished: October 29th 2025 | Updated:
- Study Design and Preliminary Results From the TRUCKEE Study Evaluating Faricimab in Real-World Neovascular AMD Patients
Published: April 18th 2023 | Updated:
Advertisement
Advertisement
Trending on Modern Retina
1
How European clinicians are revolutionizing retina care
2
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
3
Clinical Insights Shaping Real-World Decision-Making in Geographic Atrophy
4
Managing Geographic Atrophy in a 90-Year-Old Patient with Coexisting Neovascular AMD and Recurrent CNV Activation
5
